Gaithersburg company, Canadian government reach COVID-19 vaccine agreement


GAITHERSBURG, Md. (WDVM) — A Gaithersburg-based biotech company has reached a COVID-19 vaccine agreement with the Canadian government.

Novavax will provide Canada with up to 76 million doses of its COVID-19 vaccine. Novavax says it will supply those doses to the Canadian government as early as the second quarter of next year, 2021. A release from Novavax says the company and the Canadian government are working to finalize an advance purchase agreement.

Stanley Erck, the President and CEO of Novavax said in a statement, “we are pleased to work with the Canadian government on supply of our COVID-19 vaccine, an essential step to ensure broad access of our vaccine candidate.”

Back in July, the United States government gave Novavax $1.6 billion to help fund the development of a vaccine as part of Operation Warp Speed. The company has secured over $2 billion in total funding.

The vaccine candidate, NVX-CoV2373, is currently in Phase 2 of clinical trials.

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Local News Headlines

Stay Connected


Don't Miss

More Local News

Trending Stories